about
Combination Approaches with Immune-Checkpoint Blockade in Cancer TherapyRecent advances in understanding antitumor immunityRecent Advances in Immunotherapy in Metastatic NSCLCManufacturing Natural Killer Cells as Medicinal ProductsThe role of immune checkpoint inhibition in the treatment of ovarian cancerControl of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors.Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival.PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression.Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.Interlaboratory-concordance of PD-L1 immunohistochemistry for non-small cell lung cancer.Challenges faced when identifying patients for combination immunotherapy.PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidenceCheckpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Combining radiotherapy with immunotherapy: the past, the present and the future.Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments.Immunoplasticity in cutaneous melanoma: beyond pure morphology.Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Pembrolizumab for the treatment of non-small cell lung cancer.Implementing liquid biopsies into clinical decision making for cancer immunotherapy.Adoptive T cell therapy: An overview of obstacles and opportunities.The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.The immune contexture in cancer prognosis and treatment.Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management.Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.Elevated Foxp3/CD8 Ratio in Lung Adenocarcinoma Metastatic Lymph Nodes Resected by Transcervical Extended Mediastinal LymphadenectomyDermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer.PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.Prognostic Significance of Host-related Biomarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer.PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells.Awakening immunity against cancer: a 2017 primer for clinicians.A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC.Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016.The Challenge for Development of Valuable Immuno-oncology Biomarkers.The Future of Radiobiology.
P2860
Q28066199-F73E2D12-DB43-4A8E-81F8-325F8C8D6F40Q28067217-CA2AA233-EA30-454E-A315-7F25B9DF2F1DQ28069323-17C0FB39-E102-456A-BA3E-FFFB1F336EDEQ28069992-B806155F-A57C-4F64-8296-5B0A7429FE26Q28077924-03B8217D-FCF3-45AB-87A9-39C6DD592121Q29994573-896572EF-1CF0-472B-B01E-8C65ED46E92DQ33803754-2EF041D2-879F-44EA-A189-A7DD857C5D51Q36276257-92967508-15E4-44E7-A27B-15CF08F273ACQ37486606-87B04154-2553-4E37-A046-0951B5A89EABQ37662425-DCF4CD04-7F1C-416B-A310-40387748217BQ38438763-D061F65F-FDC3-4D4C-B7C9-7AFF52BAD0E9Q38603546-5523049F-2AE8-4821-8E40-56BBDA517E46Q38638046-BBB18F2B-D2A8-4199-9080-F1802BD7A4B8Q38649562-3AE0676D-B5F8-45F1-91D1-C0B4C976FC9DQ38672084-5A6A7AD3-560D-4A64-95B4-C26E1C1E428AQ38679418-5793BFBE-0010-4F7A-8BC8-CF71C8AAA483Q38696133-CB1A7998-2FBA-45F5-8B39-DEB42E4796F8Q38754730-C48E247F-4306-4EAE-BD73-FBEB893E94E0Q39067933-67B3B468-78C6-44BE-8681-F5D0F3D06322Q39069273-8EEE225D-FD43-43E9-817D-60900A7DFB0DQ39130451-88E379EA-3A3C-4841-B3C2-DD1100CAE7EAQ39198286-F018FE33-7492-4E7B-8E39-3E9F7193474FQ39304648-C1AFA464-7070-4249-A9C9-44C7D69C9031Q39329596-70ADA1CD-B82D-4742-8B1C-2E99C8403EF2Q39341329-1F7D9FC9-BE80-4925-977A-0316B60F8594Q39456999-9C3B3896-C9ED-44F7-9E01-FA42A124B25EQ40115962-BDB2C593-A942-4E93-8D00-9A3B35462B2CQ40226135-FBE87F61-0BDC-46C5-A0E4-1E035AE276D3Q40226483-10DB4896-8826-4245-A2A1-50F6939632A7Q40282288-6D5B4CF1-1F2B-4536-8ADA-4574919793F6Q41430954-E9148782-FACB-4FFE-9D24-501D457227E5Q41485219-3AE2CB26-D07A-4CF4-8909-CFAC55B6D75EQ41550899-18936195-6B40-4788-9A42-7844138F1084Q41721668-23C3ED77-FD49-456A-9950-4313F760D808Q42253745-C32C7735-C115-406F-A489-0AABBC5B26ACQ42347636-BBEEDA3A-E802-4E86-9B27-92583B0F42C9Q42362351-CE438EFF-DAAA-46E4-B4E0-0C3CD9ECB517Q42397300-B216DE6E-DCED-47BA-9F7C-F834E7A1DEAEQ46008297-1AB2B6D0-221E-4724-9D0F-E81918F71203Q46136392-E50612AC-EF7F-404B-949A-737F082E618D
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
CANCER IMMUNOLOGY. The "cancer immunogram".
@ast
CANCER IMMUNOLOGY. The "cancer immunogram".
@en
type
label
CANCER IMMUNOLOGY. The "cancer immunogram".
@ast
CANCER IMMUNOLOGY. The "cancer immunogram".
@en
prefLabel
CANCER IMMUNOLOGY. The "cancer immunogram".
@ast
CANCER IMMUNOLOGY. The "cancer immunogram".
@en
P2093
P356
P1433
P1476
CANCER IMMUNOLOGY. The "cancer immunogram".
@en
P2093
Antoni Ribas
Christian U Blank
John B Haanen
P304
P356
10.1126/SCIENCE.AAF2834
P407
P577
2016-05-01T00:00:00Z